Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin combination.

Abstract

The authors assessed the prevalence of headaches following extended-release dipyridamole/aspirin combination (DAC), and the efficacy of acetaminophen in the treatment of these headaches. Following DAC, 38.7% of the participants developed headaches. The headaches were self-limited (69.4% placebo efficacy in 2 hours) and the incidence markedly declined over time. Acetaminophen was no more effective than placebo in the acute and preemptive treatment of these headaches.

• Authors: R B Lipton, M E Bigal, K B Kolodner, P B Gorelick, K Wilks, M Schoebelock, G Davidai
• Journal: Neurology (Neurology) Vol. 63 Issue 6 Pg. 1099-101 (Sep 28 2004) ISSN: 1526-632X [Electronic] United States
• PMID: 15452309 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Analgesics, Non-Narcotic
• Drug Combinations
• Acetaminophen
• Dipyridamole
• Aspirin

Topics

• Acetaminophen (therapeutic use)
• Aged
• Analgesics, Non-Narcotic (therapeutic use)
• Aspirin (administration & dosage, adverse effects)
• Dipyridamole (administration & dosage, adverse effects)
• Drug Combinations
• Female
• Headache (chemically induced, drug therapy, prevention & control)
• Humans
• Incidence
• Male
• Middle Aged
• Prevalence
• Remission, Spontaneous
• Risk
• Treatment Failure